Arcadia Biosciences Q3 2023 EPS $(1.89) Beats $(3.19) Estimate, Sales $1.60M Beat $1.55M Estimate
Portfolio Pulse from totan@benzinga.com
Arcadia Biosciences (NASDAQ:RKDA) reported Q3 2023 earnings with losses of $(1.89) per share, beating the analyst consensus estimate of $(3.19) by 40.75%. This is a 60.63% increase over losses from the same period last year. The company also reported quarterly sales of $1.60 million, beating the analyst consensus estimate of $1.55 million by 3.03%, but this is a 14.96% decrease over sales from the same period last year.
November 09, 2023 | 9:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Arcadia Biosciences reported better than expected Q3 2023 earnings, with losses and sales beating analyst estimates. However, sales decreased compared to the same period last year.
Arcadia Biosciences reported better than expected earnings, which is generally a positive signal for the stock. However, the decrease in sales compared to the same period last year might be a concern for investors, potentially limiting the positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100